Smoking Clinical Trial
Official title:
A Randomized, Double-Blind Study of the Biological Effects and Tolerability of Celecoxib as a Chemopreventive Agent in Current and Former Smokers
The purpose of this study is:
- To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell
proliferation, in the bronchial epithelium of current and former smokers.
- To examine the toxicity associated with celecoxib administration.
- To measure the effect of celecoxib treatment on arachidonic acid metabolites in the
bronchial epithelium of current and former smokers.
COX-2 is an enzyme thought to be involved in the development of some cancer. Celecoxib is a
COX-2 inhibitor.
Before treatment begins, participants will have a bronchoscopy (tissue sample from the
lung). This is taken to see if different elements (biomarkers) in the tissue can predict
which individuals are at higher risk for developing cancer. In a bronchoscopy a tube will be
placed through the nose into the lung (while under sedation) to remove tissue samples for
laboratory analysis (biopsy). Cells will also be collected during the bronchoscopy by
spraying the lungs with a small amount water and then removing the water (bronchial lavage,
bronchial washing). In addition, a sputum sample will be taken and the inside of the cheek
will be scraped (buccal sample).
A complete physical exam will be performed before beginning treatment and at 1, 2, 3, 4, 5,
and 6 months. During these visits, participants will be asked questions about
tobacco/alcohol exposure. Participants will have blood taken before beginning treatment and
at 1, 3, 4, and 6 months. Urine samples will be taken before beginning treatment and at 3
and 6 months. The research nurse will also ask participants about any adverse signs or
symptoms that they have experienced. Participants who smoke will be encouraged to stop
smoking. Sources for assistance to stop smoking will be provided for all study participants
who continue to smoke.
In this study, participants will be randomly picked (as in the toss of a coin) to be in one
of four treatment groups. Treatment in this study will last 6 months. Participants in the
first group will receive a placebo during all 6 months. A placebo is a substance that looks
like the study drug but is inactive. Participants in the second group will receive a placebo
during Months 1-3 and Celecoxib during Months 4-6. Participants in the third group will
receive Celecoxib during Months 1-3 and placebo during Months 4-6. Participants in the
fourth group will receive Celecoxib during all 6 months. Neither the participant nor the
participant's doctor will know to which treatment group the participant was assigned.
Participants have an equal chance of being assigned to any of these groups.
Participants will take 2 capsules twice a day for the 6-month treatment period. The capsule
could be either a placebo or the study drug.
At 3 and 6 months, participants will have a physical exam, blood tests, and a bronchoscopy.
Participants should take their study medication with a sip of water 2 hours before each
bronchoscopy with a sip of water. Sputum and buccal samples will also be taken at these
times. The research nurse will ask participants questions about changes and/or additions to
the medications.
This is an investigational study. The use of Celecoxib in the prevention of lung cancer is
investigational. Up to 250 individuals will take part in this study. All will be enrolled at
the M. D. Anderson.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
| Completed |
NCT02649556 -
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
|
N/A | |
| Completed |
NCT03901066 -
Smoking Dependence and Periodontitis
|
||
| Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
| Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
| Completed |
NCT03305978 -
Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
|
N/A | |
| Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
| Completed |
NCT06105424 -
BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability
|
N/A | |
| Active, not recruiting |
NCT02752022 -
Monitoring the Transition From Smoking to E-cigarettes
|
||
| Completed |
NCT04340830 -
The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants
|
N/A | |
| Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
| Completed |
NCT02912000 -
TEACH: Technology Evaluation to Address Child Health
|
N/A | |
| Completed |
NCT02901171 -
The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation
|
N/A | |
| Completed |
NCT02949648 -
Electronic Cigarette Use and Quitting in Youth
|
N/A | |
| Completed |
NCT02246114 -
Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women
|
N/A | |
| Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
| Completed |
NCT01954407 -
Young Adults' Responses to Anti-smoking Messages
|
N/A | |
| Completed |
NCT02008292 -
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
|
N/A | |
| Completed |
NCT01898507 -
Nicotine Metabolism and Low Nicotine Cigarettes
|
N/A |